


Overview of Lenacapavir (LEN) for PrEP Trials

- ★ Initial data
- ★ Possible data
- ✓ Possible earliest regulatory submissions
- ✓ Possible earliest regulatory approval and market entry with product from Gilead
- ★ Possible earliest generic manufacturer(s)



Trial	Population	Location	Size	2022	2023	2024	2025	2026	2027	2028	
 PURPOSE 1 Phase 3 Injectable lenacapavir & oral F/TAF	Cisgender adolescent girls and young women	South Africa and Uganda	5,345	Initial results released in June 2024 demonstrated no infections in the LEN arm							
 PURPOSE 2 Phase 3 Injectable lenacapavir	Cisgender men who have sex with men, Transgender women, Transgender men, Gender non- binary	US, South Africa, Peru, Brazil, Mexico, Argentina, and Thailand	3,271	Initial results released in September 2024 demonstrated LEN reduced HIV infections by 96% compared to background HIV incidence							
 PURPOSE 3 HPTN 102 Phase 2 Injectable lenacapavir	Cisgender women	US	253	Currently recruiting; estimated study completed date early 2028							
 PURPOSE 4 HPTN 103 Phase 2 Injectable lenacapavir	People who inject drugs	US	181	Currently recruiting; estimated study completed date mid-2027							
 PURPOSE 5 Phase 2 Injectable lenacapavir	Cisgender men who have sex with men, Transgender women, Transgender men, Gender non- binary	France, and UK	268	Enrollment expected to begin in the second half of 2024							
 PURPOSE 365 Phase 3 Injectable lenacapavir	Diverse population of people who would benefit from PrEP	US	300	Currently recruiting; estimated study completion date 2028							